Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
Variability in valacyclovir bioavailability and the potential for cephalexin-valacyclovir interaction were evaluated. The intraindividual acyclovir area under the concentration-time curve (AUC) varied minimally, whereas interindividual differences were substantial. Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC. These results suggest a stable valacyclovir absorption phenotype, significant interindividual variability, and minimal interaction between these hPEPT1 substrates.
Phan
Dana D
DD
School of Pharmacy, University of California, San Francisco, California 94143, USA.
Chin-Hong
Peter
P
Lin
Emil T
ET
Anderle
Pascale
P
Sadee
Wolfgang
W
Guglielmo
B Joseph
BJ
D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D002506:Cephalexin / Q000008:administration & dosage*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D000074011:Peptide Transporter 1; D027981:Symporters; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D002352:Carrier Proteins; D000074011:Peptide Transporter 1; C082186:SLC15A1 protein, human; D027981:Symporters; D014633:Valine; D000077483:Valacyclovir; D002506:Cephalexin; D000212:Acyclovir